AbbVie is a research-based biopharmaceutical company focused on developing and marketing innovative therapies in several key therapeutic areas including immunology, oncology, neuroscience, and ophthalmology.
This financial report details the characteristics and ultimate redemption of a bond issued by AbbVie, the global biopharmaceutical company specializing in pharmaceuticals and biotechnology, identified by ISIN USU0029QBB15 and CUSIP U0029QBB1; originally issued in the United States and denominated in USD, this obligation had a total issue size of $244,575,000, featured a fixed annual interest rate of 2.8% paid semi-annually, and was available for purchase in minimum increments of $2,000, ultimately reaching its maturity on March 14, 2023, at which point it was redeemed at 100% of its face value.
|
Français
Italiano
United States
USU0029QBB15 ( in USD )
